Real World Healthcare Resource Utilization (HRU) and Costs Associated With Mantle Cell Lymphoma (MCL) Therapies in the Frontline (1L) and Relapsed/Refractory (R/R) Setting
Author(s)
Nilanjan Ghosh, MD, PhD1, Dureshahwar Jawaid, MPH2, Nnadozie Emechebe, MPH, PhD2, Beenish S. Manzoor, MPH, PhD2, Mazyar Shadman, MD, MPH3;
1Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, USA, 2AbbVie Inc., North Chicago, IL, USA, 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA
1Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, USA, 2AbbVie Inc., North Chicago, IL, USA, 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Presentation Documents
OBJECTIVES: As the treatment landscape evolves for Mantle Cell Lymphoma (MCL), understanding treatment patterns and burden of illness may inform clinical decision-making. We assessed real world healthcare resource utilization (HRU) and costs for patients (pts) with MCL in the 1L and R/R setting.
METHODS: We conducted a retrospective study using administrative claims data from Optum Clinformatics Data Mart of pts diagnosed with MCL from Jan 2017 to Sept 2023. Pts were required to be ≥18 years of age and received ≥1 approved medication for MCL. All-cause and MCL-specific total healthcare costs were obtained as a sum of medication and medical costs. Healthcare costs and HRU were expressed as per pt per month (PPPM).
RESULTS: A total of 949 pts in 1L [CT/CIT: 71.2%; BTKis: 10.6%; antiCD20s: 13.1%; other targeted agents: 5.0%; CAR-T: 0.1%] were included with a median age of 73.0 years. Mean all-cause costs were $20,826 PPPM [BTKi: $24,410; CT/CIT: $20,948; CAR-T: $19,143]. 57.4% and 55.5% of pts receiving BTKis and CT/CIT, respectively, had ≥1 hospitalization with a mean duration of 3.3 and 2.1 days.
In second line (n=262), pts demonstrated increased utilization of BTKis and CAR-T [54.2% and 2.3%, respectively] and a decrease of CT/CIT [25.6%]. Mean all-cause total costs increased to $26,536 PPPM [BTKi: $28,888; CT/CIT: $25,210; CAR-T: $47,670]. 48.6%, 60.0% and 100% of pts receiving BTKis, CT/CIT and CAR-T, respectively had ≥1 hospitalization PPPM [mean duration 4.4, 3.2 and 6.6 days, respectively].
Similar trends were observed in third line (n=79). MCL-specific costs and HRU also showed a similar pattern across lines of therapy.
CONCLUSIONS: Increased utilization and higher mean costs were observed with BTKis and CAR-Ts across line of therapies in MCL. These results demonstrate the need for consideration of costs/HRU in MCL clinical decision-making, especially with respect to possible financial toxicity for patients.
METHODS: We conducted a retrospective study using administrative claims data from Optum Clinformatics Data Mart of pts diagnosed with MCL from Jan 2017 to Sept 2023. Pts were required to be ≥18 years of age and received ≥1 approved medication for MCL. All-cause and MCL-specific total healthcare costs were obtained as a sum of medication and medical costs. Healthcare costs and HRU were expressed as per pt per month (PPPM).
RESULTS: A total of 949 pts in 1L [CT/CIT: 71.2%; BTKis: 10.6%; antiCD20s: 13.1%; other targeted agents: 5.0%; CAR-T: 0.1%] were included with a median age of 73.0 years. Mean all-cause costs were $20,826 PPPM [BTKi: $24,410; CT/CIT: $20,948; CAR-T: $19,143]. 57.4% and 55.5% of pts receiving BTKis and CT/CIT, respectively, had ≥1 hospitalization with a mean duration of 3.3 and 2.1 days.
In second line (n=262), pts demonstrated increased utilization of BTKis and CAR-T [54.2% and 2.3%, respectively] and a decrease of CT/CIT [25.6%]. Mean all-cause total costs increased to $26,536 PPPM [BTKi: $28,888; CT/CIT: $25,210; CAR-T: $47,670]. 48.6%, 60.0% and 100% of pts receiving BTKis, CT/CIT and CAR-T, respectively had ≥1 hospitalization PPPM [mean duration 4.4, 3.2 and 6.6 days, respectively].
Similar trends were observed in third line (n=79). MCL-specific costs and HRU also showed a similar pattern across lines of therapy.
CONCLUSIONS: Increased utilization and higher mean costs were observed with BTKis and CAR-Ts across line of therapies in MCL. These results demonstrate the need for consideration of costs/HRU in MCL clinical decision-making, especially with respect to possible financial toxicity for patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE436
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology